What is AdAlta?
AdAlta operates at the vanguard of protein engineering, leveraging its unique i-body technology to address complex medical conditions that remain resistant to conventional antibody treatments. By focusing on high-unmet-need areas such as fibrosis and immuno-oncology, the company has carved out a specialized niche in the biopharmaceutical landscape. Its lead candidate, AD-214, represents a significant advancement in therapeutic protein design, while its broader pipeline—including i-CAR-T cell therapies and i-PET imaging—positions the firm as a multifaceted innovator in precision medicine. The company's ability to bridge the gap between early-stage research and clinical-grade therapeutic solutions is central to its current market valuation and strategic positioning.
How much funding has AdAlta raised?
AdAlta has raised a total of $2.1M across 2 funding rounds:
Other Financing Round
$325K
Stock/Share Issuance
$1.8M
Other Financing Round (2025): $325K, investors not publicly disclosed
Stock/Share Issuance (2026): $1.8M, investors not publicly disclosed
Key Investors in AdAlta
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for AdAlta?
With this recent capital infusion, AdAlta is well-positioned to scale its operational capabilities and advance its clinical trial programs. The strategic roadmap likely involves intensifying the development of AD-214, while simultaneously diversifying its portfolio through the maturation of its i-CAR-T cell therapy initiatives. Investors and industry observers will be monitoring the company's progress in navigating the regulatory landscape and its potential for future strategic partnerships or licensing agreements. As the firm continues to refine its i-body platform, the focus will remain on demonstrating clinical efficacy and safety, which are essential for long-term value creation in the competitive biotechnology market.
See full AdAlta company page
